Compare OCFC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | HROW |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1996 | 2008 |
| Metric | OCFC | HROW |
|---|---|---|
| Price | $18.90 | $37.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $21.67 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 967.2K | 540.7K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ 0.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $47.51 | $31.62 |
| Revenue Next Year | $21.97 | $50.77 |
| P/E Ratio | $69.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $28.54 |
| 52 Week High | $20.61 | $54.98 |
| Indicator | OCFC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 39.04 |
| Support Level | $17.31 | $32.74 |
| Resistance Level | $19.35 | $42.40 |
| Average True Range (ATR) | 0.31 | 1.93 |
| MACD | -0.06 | -0.30 |
| Stochastic Oscillator | 20.18 | 13.16 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.